- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00000322
Tyrosine for Methamphetamine Dependence - 1
January 11, 2017 updated by: National Institute on Drug Abuse (NIDA)
Tyrosine for Methamphetamine Dependence
The purpose of this study is to evaluate efficacy of tyrosine as a treatment for methamphetamine dependence in an outpatient treatment setting providing group psychosocial interventions.
Examine effect of tyrosine on abstinence, retention in treatment, and craving."
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Evaluate efficacy of tyrosine as a treatment for methamphetamine dependence in an outpatient treatment setting providing group psychosocial interventions.
Examine effect of tyrosine on abstinence, retention in treatment and craving.
Study Type
Interventional
Enrollment
89
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States, 94117
- Haight Ashbury Free Clinics
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
18-65 years of age. Able to provide informed consent. Desire to reduce/eliminate methamphetamine use. Used within the past two weeks. Meet DSM criteria for methamphetamine dependence.
Exclusion Criteria:
No dependence (within the past 12 months) for other durgs except nicotine. No history or family history of tyrosine intolerance.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Craving
|
Drug use
|
Retention
|
Functioning
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Gantt Galloway, Pharm.D., Haight Ashbury Free Clinics
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 1997
Study Completion
December 1, 2001
Study Registration Dates
First Submitted
September 20, 1999
First Submitted That Met QC Criteria
September 20, 1999
First Posted (Estimate)
September 21, 1999
Study Record Updates
Last Update Posted (Estimate)
January 12, 2017
Last Update Submitted That Met QC Criteria
January 11, 2017
Last Verified
April 1, 1997
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NIDA-10739-1
- R01-10739-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Amphetamine-Related Disorders
-
National Taiwan University HospitalUnknownMethamphetamine Dependence | Methamphetamine Abuse | Amphetamine Dependence | Amphetamine AbuseTaiwan
-
University of PennsylvaniaNational Institute on Drug Abuse (NIDA); Society of Alcoholism and other AddictionsCompletedAmphetamine DependenceIceland
-
Shanghai Mental Health CenterCompletedAmphetamine AddictionChina
-
Friends Research Institute, Inc.National Institute on Drug Abuse (NIDA)Completed
-
Centre hospitalier de l'Université de Montréal...Withdrawn
-
Shanghai Mental Health CenterCompleted
-
University of VirginiaAmerican Association of Chairs of Departments of PsychiatryWithdrawnAmphetamine DependenceUnited States
-
The University of New South WalesSt Vincent's Hospital, Sydney; Australian Government Department of Health and... and other collaboratorsUnknown
-
Shanghai Mental Health CenterRecruitingAmphetamine AddictionChina
-
California Pacific Medical Center Research InstituteUnknownSubstance Dependence | Amphetamine DependenceUnited States
Clinical Trials on Tyrosine
-
Seton Healthcare FamilyCompleted
-
University of FloridaTerminated
-
Icahn School of Medicine at Mount SinaiTerminated
-
Assiut UniversityNot yet recruiting
-
New York Institute of TechnologyCompletedBlood PressureUnited States
-
New York Institute of TechnologyMichael J. Fox Foundation for Parkinson's ResearchCompletedParkinson's DiseaseUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)Terminated
-
Thomas HopeActive, not recruitingRecurrent Glioblastoma | Recurrent WHO Grade III Glioma | Low Grade Glioma | Intracranial Neoplasm | Recurrent World Health Organization (WHO) Grade II GliomaUnited States
-
Zhejiang UniversityUnknownNon Small Cell Lung CancerChina
-
BayerCompletedSolid CancerGermany, Italy, United States, Japan, United Kingdom